Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways

Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways

US Patent 10226468 · Granted Mar 12, 2019

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Synchronous business process execution engine for action orchestration in a sing2025
Small molecule inhibitors of TEAD transcription factors2025
P2X3 and/or P2X2/3 compounds and methods2024
Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cance2024
Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cance2024
Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cance2024
P2X3 and/or P2X2/3 compounds and methods2023
PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereo2023
Substituted imidazolidin-2-one derivatives as PRMT5 inhibitors2023
Protein-polymer-drug conjugates2022
Markers of tissue aging and uses therefor2022
Imidazolidin-2-one compounds as PRMT5 modulators2022